nCage Therapeutics

nCage Therapeutics is an early-stage biotech leveraging its proprietary TRAP-cage platform to design synthetic virus-like particles for vaccine and drug delivery applications. The platform's key differentiators include programmable opening/closing for cargo loading and the ability to display biomolecules in precise arrays. The company is advancing preclinical programs in respiratory vaccines and oncology ADCs, supported by strategic collaborations with academia and industry partners like MSD. As a private, pre-revenue entity, nCage is building a foundation of intellectual property and proof-of-concept data to attract further partnership and investment.

Proprietary TRAP-cage platform: engineered bacterial TRAP proteins that self-assemble into synthetic, programmable virus-like particles (VLPs) capable of surface display of antigens or encapsulation of therapeutic cargo (proteins, nucleic acids, small molecules) for targeted delivery.

nCage competes in the crowded field of synthetic VLP vaccine developers (e.g., SpyBiotech, VLP Therapeutics) and nanoparticle drug delivery companies. Its differentiation lies in the unique programmable opening/closing mechanism of its TRAP-based cages. Success will depend on demonstrating clear advantages in immunogenicity, payload capacity, or manufacturing over rival platforms.